Add BrightSurf on Google Email

Heart researchers unpack neutral findings from ZEUS, an anti-inflammatory clinical trial

A global phase 3 clinical trial, ZEUS, tested a drug targeting interleukin-6, but found no reduction in cardiovascular event rates compared to placebo. The study's neutral findings suggest moving upstream to find the right target, while acknowledging the effectiveness of downstream IL-6 inhibition in modifiable earlier stage disease.

SourceMass General Brigham·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateNov 7, 2026

Plant-derived anti-inflammatory compounds: Bridging the translation gap from molecular targets to therapeutic candidates

The review proposes an evidence framework to separate direct target engagement from downstream effects in plant-derived anti-inflammatory drug discovery. Plant-derived compounds exhibit pleiotropy, influencing multiple inflammatory pathways, but direct target binding and downstream effects are distinct.

SourceImmunity & Inflammation·JournalImmunity & Inflammation·TypeSystematic review·DateNov 5, 2026

Maternal immune activation (MIA) reshapes placental development

Researchers investigated the effects of early-gestational maternal immune activation on placental development, revealing persistent structural remodeling, sexually dimorphic metabolic adaptations, and compensatory extracellular matrix responses. ITGB1 was identified as a candidate mediator of placental adaptation to inflammatory stress.

SourceCompuscript Ltd·JournalGenes & Diseases·DateOct 30, 2026

Inflammation is already elevated at the earliest stage of cardiovascular-kidney-metabolic syndrome

A new analysis of US national health data found that inflammation increases across the stages of cardiovascular-kidney-metabolic syndrome, with the largest increase at the earliest stage. Average hs-CRP nearly doubled between stage 0 and stage 1, crossing the 2 mg/L threshold commonly used to signal increased cardiovascular risk.

SourceUniversity of Eastern Finland·JournalEuropean Journal of Preventive Cardiology·DateOct 14, 2026

Of mice and zebrafish: how MSK scientists solved a decades-old mystery and uncovered new insights about inflammation

Researchers at Memorial Sloan Kettering Cancer Center identify a critical inflammatory signaling pathway and its role in protecting healthy cells from immune response damage. The discovery opens new avenues for understanding diseases where inflammation runs amok, including cancer, inflammatory bowel disease, and asthma.

SourceMemorial Sloan Kettering Cancer Center·JournalNature·TypeExperimental study·DateOct 7, 2026

Computer-designed protein targets immune receptor linked to inflammation at a new “undruggable” site

Scientists at Scripps Research engineered a synthetic protein that can bind to TLR4 within cell membranes, reducing inflammatory signals. The study advances understanding of TLR4's membrane-embedded region, which is critical for cross-membrane signaling, and outlines new computational tools for targeting proteins within membranes.

SourceScripps Research Institute·JournalProceedings of the National Academy of Sciences·DateOct 1, 2026

ILC2 cells emerge as key cellular interfaces bridging nervous and immune systems

Group 2 innate lymphoid cells (ILC2s) form tight anatomical associations with sensory, autonomic, and enteric nerve fibers, receiving neural regulation through activating and inhibitory pathways. ILC2s also secrete cytokines that can act back on neurons, forming positive feedback loops that modulate allergic and anti-infective immunity.

SourceImmunity & Inflammation·JournalImmunity & Inflammation·TypeSystematic review·DateSep 25, 2026

AI model uses routine imaging to identify patients at risk for serious treatment-induced lung inflammation

Researchers developed an AI model that uses routine chest CT scans to identify patients at risk of pneumonitis, a potentially life-threatening form of lung inflammation. The model, called CIPHER, achieved high predictive power and maintained strong performance despite differences in patient populations and imaging protocols.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalJournal for ImmunoTherapy of Cancer·DateSep 24, 2026

Target identified in treatment of neuroHIV

A new study by UC Riverside scientists has identified MAPK14, a brain protein, as the driving force behind neuroHIV damage, which causes dementia, neuropathy, and memory problems. By targeting this protein, researchers hope to develop a treatment for neuroHIV, a condition affecting millions worldwide.

SourceUniversity of California - Riverside·JournalBrain Behavior and Immunity·TypeExperimental study·DateSep 22, 2026

‘Invisible’ inflammation in rare bowel disease may explain heightened colon cancer risk

Researchers have mapped cellular differences between two similar bowel diseases, identifying hidden immune activity that may explain why one carries a much higher risk of colon cancer. The study found that patients with PSC-associated IBD had a distinct microbiome and higher levels of immune activity even in the absence of inflammation.

SourceGarvan Institute of Medical Research·JournalNature Communications·TypeObservational study·DateSep 21, 2026

Osteoarthritis: New players involved in joint inflammation

A recent study published in Cell Death & Differentiation highlights the role of endoplasmic reticulum stress proteins in osteoarthritis, revealing their contribution to inflammation and tissue remodeling. The research identifies a promising protein, PDIA4, which may serve as a therapeutic target for limiting disease progression.

SourceUniversity of Liège·JournalCell Death and Differentiation·DateAug 31, 2026

Tissue 'glue' also helps swallow dead cells

A protein that sticks cells together has been found to also help engulf dead cells, a discovery that could lead to new clues for understanding chronic inflammatory conditions. The study found that the 'tissue glue' helps cells adapt to swallow dead cells, which are a major cause of inflammation.

SourceCenter for Genomic Regulation·JournalNature Communications·TypeExperimental study·DateAug 27, 2026

New uOttawa study suggests gene linked to Parkinson's disease holds clues to battling deadly bacterial infections

Researchers have discovered a gene linked to Parkinson's disease may also strengthen the body's ability to fight dangerous infections. The study found that a well-studied mutation in the LRRK2 gene increases the production of reactive oxygen species, making immune cells more effective at eliminating intracellular bacteria.

SourceUniversity of Ottawa·JournalCellular and Molecular Immunology·TypeImaging analysis·DateAug 19, 2026

Flexing new hope: Muscles may help protect the Parkinson's brain

Researchers found that exercise-induced molecular changes contribute to neuronal health, improving movement and quality of life in PD patients. Exercise types such as aerobic exercises, resistance training, balance training, and multimodal exercise were found to be helpful in reducing falls, disabilities, and improving brain function.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalNeuroprotection·TypeLiterature review·DateAug 7, 2026

Drug reverses autism-like brain changes in adult mice within hours, study finds

Researchers found that a single dose of rapamycin rapidly improved symptoms in adult mice with autism-like changes, reversing abnormal brain signaling and behavior within two hours. The study suggests the adult brain's functional circuitry, not just its physical structure, as a target for future treatment approaches.

SourceUniversity of California - Los Angeles Health Sciences·TypeRandomized controlled/clinical trial·DateJul 23, 2026

Early inflammation signal drives oral cancer development, highlights path for immunoprevention

A study published in Cancer Research identified an immune pathway that promotes the progression of oral precancerous lesions into head and neck squamous cell carcinoma. The researchers found that targeting a key inflammation signal known as interleukin-1 alpha (IL-1α) could help restore immune surveillance and prevent high-risk lesions...

Scientists discover how macrophages – a key type of immune cells – age differently throughout the body

A new study reveals that macrophages, a key immune cell type, age differently across tissues and between sexes. The researchers found that aging macrophages become more focused on responding to stress and cellular damage, but lose some molecular programs involved in maintaining healthy tissue structure.

SourceUniversity of Southern California·JournalBMC Biology·TypeExperimental study·DateJul 14, 2026